{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:59:47Z","timestamp":1786971587615,"version":"build-2736575974"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2003,6,24]],"date-time":"2003-06-24T00:00:00Z","timestamp":1056412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,6,24]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>X-linked hyper-IgM syndrome (HIGM1) (MIM\u266f308230), is a severe primary immunodeficiency caused by mutations in the gene coding for CD40 ligand (CD40L or CD154), a member of the tumour necrosis factor (TNF) superfamily. The interaction of this protein with its ligand, CD40, mediates crucial processes in the immune response. The variety of defects that have been described in HIGM1 patients range from a complete lack of CD40L protein expression to missense mutations that interfere with its interaction with CD40L. In this study we describe three families \u2013 a total of seven HIGM1 patients and carriers, presenting a spectrum of severity in clinical evolution. In two of these families, patient DNA samples were available for genetic studies. In the third, carrier detection was performed on female family members. The results of immunological studies \u2013 the different patterns of CD40L expression and binding capacity as measured by flow cytometry \u2013 and molecular diagnosis are presented. Three novel mutations were identified: an intron mutation that partially interferes with the splicing process (intron 3, position + 5 G\/T); a missense mutation (Ser222 Phe) located in the molecular region which interacts with the receptor and which abrogates binding capacity; and a 14 base pair deletion leading to a frameshift and a premature truncated mutation (del I 171 X 195). An attempt to correlate protein expression and function of the CD40L mutants with clinical disease evolution is described.<\/jats:p>","DOI":"10.1046\/j.1365-2249.2003.02184.x","type":"journal-article","created":{"date-parts":[[2004,12,21]],"date-time":"2004-12-21T21:53:19Z","timestamp":1103665999000},"page":"123-131","source":"Crossref","is-referenced-by-count":16,"title":["Three novel mutations reflect the variety of defects causing phenotypically diverse X-linked hyper-IgM syndrome"],"prefix":"10.1093","volume":"133","author":[{"given":"E","family":"L\u00d3PEZ-GRANADOS","sequence":"first","affiliation":[{"name":"Immunology Unit, Hospital La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"CAMBRONERO","sequence":"additional","affiliation":[{"name":"Immunology Unit, Hospital La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"FERREIRA","sequence":"additional","affiliation":[{"name":"Immunology Unit, Hospital La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"FONT\u00c1N","sequence":"additional","affiliation":[{"name":"Immunology Unit, Hospital La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M C","family":"GARC\u00cdA-RODR\u00cdGUEZ","sequence":"additional","affiliation":[{"name":"Immunology Unit, Hospital La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2003,6,24]]},"reference":[{"key":"2022011222240026800_b1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1006\/clim.1999.4799","article-title":"Diagnostic criteria for primary immunodeficiencies","volume":"93","author":"Conley","year":"1999","journal-title":"Clin Immunol"},{"key":"2022011222240026800_b2","first-page":"1","article-title":"Primary immunodeficiency diseases","volume":"118","author":"IUIS Scientific Group","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"2022011222240026800_b3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0092-8674(93)90668-G","article-title":"The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome","volume":"72","author":"Aruffo","year":"1993","journal-title":"Cell"},{"key":"2022011222240026800_b4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-065X.1994.tb00848.x","article-title":"Molecular pathology of X-linked immunoglobulin deficiency with normal or elevated IgM (HIGMX-1)","volume":"138","author":"Ramesh","year":"1994","journal-title":"Immunol Rev"},{"key":"2022011222240026800_b5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1600-065X.1994.tb00846.x","article-title":"Defective expression of CD40 ligand on T cells causes \u2018X-linked immunodeficiency with hyper-IgM (HIGM1)\u2019","volume":"138","author":"Kroczek","year":"1994","journal-title":"Immunol Rev"},{"key":"2022011222240026800_b6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/357080a0","article-title":"Molecular and biological characterization of a murine ligand for CD40","volume":"357","author":"Armitage","year":"1992","journal-title":"Nature"},{"key":"2022011222240026800_b7","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1002\/j.1460-2075.1992.tb05530.x","article-title":"The human T cell antigen gp39, a member of the THF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity","volume":"11","author":"Hollenbaugh","year":"1992","journal-title":"EMBO J"},{"key":"2022011222240026800_b8","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0969-2126(01)00239-8","article-title":"Crystal structure of an extracellular fragment of human CD40 ligand","volume":"3","author":"Karpusas","year":"1995","journal-title":"Structure"},{"key":"2022011222240026800_b9","doi-asserted-by":"crossref","first-page":"24603","DOI":"10.1074\/jbc.273.38.24603","article-title":"Detailed comparison of two molecular models of the human CD40 ligand with an X-ray structure and critical assessment of model-based mutagenesis and residue mapping studies","volume":"273","author":"Bajorath","year":"1998","journal-title":"J Biol Chem"},{"key":"2022011222240026800_b10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/PL00000776","article-title":"The CD40\/CD154 receptor\/ligand dyad","volume":"58","author":"Sch\u00f6nbeck","year":"2001","journal-title":"Cell Mol Life Sci"},{"key":"2022011222240026800_b11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jlb.67.1.2","article-title":"CD40-CD40 ligand","volume":"67","author":"Van Kooten","year":"2000","journal-title":"J Leukoc Biol"},{"key":"2022011222240026800_b12","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/0167-5699(94)90269-0","article-title":"The role of CD40 in the regulation of humoral and cell-mediated immunity","volume":"15","author":"Durie","year":"1994","journal-title":"Immunol Today"},{"key":"2022011222240026800_b13","doi-asserted-by":"crossref","first-page":"977","DOI":"10.4049\/jimmunol.158.2.977","article-title":"Cholangiopathy and tumours of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM","volume":"158","author":"Hayward","year":"1997","journal-title":"J Immunol"},{"key":"2022011222240026800_b14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-3476(97)70123-9","article-title":"Clinical spectrum of X-linked hyper-IgM syndrome","volume":"131","author":"Levy","year":"1997","journal-title":"J Pediatr"},{"key":"2022011222240026800_b15","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1086\/515633","article-title":"Parvovirus B19-induced anemia as the presenting manifestation of X-linked hyper-IgM syndrome","volume":"178","author":"Seyama","year":"1998","journal-title":"J Infect Dis"},{"key":"2022011222240026800_b16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1006\/clim.2000.4956","article-title":"Mutations in activation-induced cytidine deaminase in patients with hyper-IgM syndrome","volume":"97","author":"Minegishi","year":"2000","journal-title":"Clin Immunol"},{"key":"2022011222240026800_b17","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0092-8674(00)00079-9","article-title":"Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2)","volume":"102","author":"Revy","year":"2000","journal-title":"Cell"},{"key":"2022011222240026800_b18","doi-asserted-by":"crossref","first-page":"12614","DOI":"10.1073\/pnas.221456898","article-title":"Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM","volume":"98","author":"Ferrari","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022011222240026800_b19","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1086\/316914","article-title":"A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO)","volume":"67","author":"Zonana","year":"2000","journal-title":"Am J Hum Genet"},{"key":"2022011222240026800_b20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/85277","article-title":"Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia","volume":"2","author":"Jain","year":"2001","journal-title":"Nat Immunol"},{"key":"2022011222240026800_b21","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1006\/clin.1997.4422","article-title":"Development of a rapid whole blood flow cytometry procedure for the diagnosis of X-linked hyper-IgM syndrome patients and carriers","volume":"85","author":"O'Gorman","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"key":"2022011222240026800_b22","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/BF02265262","article-title":"Genomic structure and PCR-SSCP analysis of the human CD40 ligand gene: its application to prenatal screening for X-linked hyper-IgM syndrome","volume":"97","author":"Seyama","year":"1996","journal-title":"Hum Genet"},{"key":"2022011222240026800_b23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/humu.1155","article-title":"Analysis of Bruton's tyrosine kinase gene in Spain","volume":"18","author":"Garc\u00eda Rodr\u00edguez","year":"2001","journal-title":"Hum Mutat"},{"key":"2022011222240026800_b24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4049\/jimmunol.156.1.119","article-title":"CD40 ligand is expressed and functional on activated neonatal T cells","volume":"156","author":"Splawski","year":"1996","journal-title":"J Immunol"},{"key":"2022011222240026800_b25","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1073\/pnas.91.3.1099","article-title":"CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency","volume":"91","author":"Farrington","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022011222240026800_b26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2249.1997.tb08314.x","article-title":"Defective integration of activating signals derived from the T cell receptor (TCR) and costimulatory molecules in both CD4+ and CD8+ T lymphocytes of common variable immunodeficiency (CVID) patients","volume":"110","author":"Thon","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"2022011222240026800_b27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1365-3083.1997.d01-95.x","article-title":"IL-10 production and CD40L expression in patients with common variable immunodeficiency","volume":"46","author":"Oliva","year":"1997","journal-title":"Scand J Immunol"},{"key":"2022011222240026800_b28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0167-5699(96)80904-2","article-title":"CD40Lbase: a database of CD40L gene mutations causing X-linked hyper IgM syndrome","volume":"17","author":"Notarangelo","year":"1996","journal-title":"Immunol Today"},{"key":"2022011222240026800_b29","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1182\/blood.V92.7.2421","article-title":"Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper-IgM syndrome","volume":"92","author":"Seyama","year":"1998","journal-title":"Blood"},{"key":"2022011222240026800_b30","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.1093\/nar\/15.17.7155","article-title":"RNA splice junction of different classes of eukaryotes: sequence statistics and functional implication in gene expression","volume":"15","author":"Shapiro","year":"1987","journal-title":"Nucl Acids Res"},{"key":"2022011222240026800_b31","doi-asserted-by":"crossref","first-page":"33545","DOI":"10.1074\/jbc.274.47.33545","article-title":"CD154 variants associated with hyper-IgM syndrome can form oligomers and trigger CD40-mediated signals","volume":"274","author":"Garber","year":"1999","journal-title":"J Biol Chem"},{"key":"2022011222240026800_b32","doi-asserted-by":"crossref","first-page":"11310","DOI":"10.1074\/jbc.274.16.11310","article-title":"CD40 ligand mutants responsible for X-linked hyper-IgM symdrome associate with wild-type CD40 ligand","volume":"274","author":"Seyama","year":"1999","journal-title":"J Biol Chem"},{"key":"2022011222240026800_b33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1365-2567.2000.00943.x","article-title":"A polymorphic CD40 ligand (CD154) molecule mediates CD40-dependent signalling but interferes with the ability of soluble CD40 to functionally block CD154: CD40 interactions","volume":"99","author":"Barnhart","year":"2000","journal-title":"Immunology"},{"key":"2022011222240026800_b34","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1074\/jbc.C000674200","article-title":"CD154 variant lacking tumour necrosis factor homologous domain inhibits cell surface expression of wild-type protein","volume":"276","author":"Su","year":"2001","journal-title":"J Biol Chem"},{"key":"2022011222240026800_b35","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1021\/bi00006a003","article-title":"Identification of residues on CD40 and its ligand which are critical for the receptor\u2013ligand interaction","volume":"34","author":"Bajorath","year":"1995","journal-title":"Biochemistry"},{"key":"2022011222240026800_b36","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0968-0004(00)01561-9","article-title":"Cn3D: sequence and structure views for Entrez","volume":"25","author":"Wang","year":"2000","journal-title":"Trends Biochem Sci"},{"key":"2022011222240026800_b37","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/pro.5560070506","article-title":"The role of polar interactions in the molecular recognition of CD40L with its receptor CD40","volume":"7","author":"Singh","year":"1998","journal-title":"Protein Sci"},{"key":"2022011222240026800_b38","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/pro.5560050316","article-title":"Classsification of mutations in the human CD40 ligand, gp39, that are associated with X-linked hyper-IgM syndrome","volume":"5","author":"Bajorath","year":"1996","journal-title":"Protein Sci"},{"key":"2022011222240026800_b39","first-page":"1101","article-title":"Genetic control of X inactivation and processes leading to X-inactivation skewing","volume":"58","author":"Belmont","year":"1996","journal-title":"Am J Hum Genet"},{"key":"2022011222240026800_b40","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/(SICI)1521-4141(199901)29:01<367::AID-IMMU367>3.0.CO;2-4","article-title":"CD40 ligand expression deficiency in a female carrier of the X-linked hyper IgM syndrome as a result of X chromosome lyonization","volume":"29","author":"De Saint Basile","year":"1999","journal-title":"Eur J Immunol"},{"key":"2022011222240026800_b41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/clim.2000.4994","article-title":"Immunologic reconstitution following bone marrow transplantation for X-linked Hyper IgM syndrome","volume":"98","author":"Duplantier","year":"2001","journal-title":"Clin Immunol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2249.2003.02184.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2249.2003.02184.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/133\/1\/123\/42143723\/j.1365-2249.2003.02184.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/133\/1\/123\/42143723\/j.1365-2249.2003.02184.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:57:04Z","timestamp":1682902624000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/133\/1\/123\/6469393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6,24]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2003,6,24]]},"published-print":{"date-parts":[[2003,6,24]]}},"URL":"https:\/\/doi.org\/10.1046\/j.1365-2249.2003.02184.x","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2003,7]]},"published":{"date-parts":[[2003,6,24]]}}}